Your browser is no longer supported. Please, upgrade your browser.
TORC resTORbio, Inc. daily Stock Chart
resTORbio, Inc.
Index- P/E- EPS (ttm)-2.18 Insider Own48.40% Shs Outstand28.50M Perf Week-6.99%
Market Cap246.52M Forward P/E- EPS next Y-2.36 Insider Trans- Shs Float12.45M Perf Month-22.97%
Income-40.30M PEG- EPS next Q-0.42 Inst Own41.90% Short Float13.91% Perf Quarter-4.84%
Sales- P/S- EPS this Y79.20% Inst Trans0.36% Short Ratio11.09 Perf Half Y-
Book/sh6.06 P/B1.43 EPS next Y-34.90% ROA- Target Price28.75 Perf Year-
Cash/sh4.76 P/C1.82 EPS next 5Y23.60% ROE- 52W Range7.55 - 21.10 Perf YTD-48.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.00% Beta-
Dividend %- Quick Ratio20.00 Sales past 5Y- Gross Margin- 52W Low14.63% ATR0.75
Employees7 Current Ratio20.00 Sales Q/Q- Oper. Margin- RSI (14)41.24 Volatility5.84% 8.52%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close8.67
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume156.07K Price8.65
Recom1.30 SMA20-6.96% SMA50-11.48% SMA200-28.22% Volume72,577 Change-0.23%
Jul-11-18 02:07PM  resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older GlobeNewswire +10.98%
Jun-12-18 08:00AM  resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development GlobeNewswire
Jun-01-18 08:00AM  resTORbio to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 04:30PM  resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition GlobeNewswire
May-10-18 04:01PM  resTORbio Reports First Quarter 2018 Financial Results GlobeNewswire
May-09-18 04:05PM  resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire +12.44%
08:30AM  resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly GlobeNewswire
May-01-18 04:05PM  resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire +7.33%
Mar-29-18 04:05PM  resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire -9.28%
12:21PM  A Cambridge biotech is the worst-performing IPO so far this year nationally American City Business Journals
Mar-19-18 08:00AM  resTORbio Announces Formation of Clinical Advisory Board GlobeNewswire
Feb-20-18 04:26PM  Four Reasons Behind BofA's Bullish Restorbio Initiation Benzinga
08:00AM  resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-14-18 10:00AM  resTORbio, Inc. (Nasdaq: TORC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Jan-30-18 04:01PM  resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-29-18 07:30AM  [$$] Biotech's Brisk March Into Public Markets The Wall Street Journal
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.